Menu

Another CAR-T IPO

Cellectis goes public for a whopping $228 million—nearly double the value the company filed for in February.

Apr 6, 2015
Jef Akst

FLICKR, REYNERMEDIAThe Paris-based biotech Cellectis has joined a handful of other companies in going public with its chimeric antigen receptor (CAR) T-cell therapies, grossing more than $228 million in its initial public offering (IPO) on the Nasdaq last month (March 24). That value is $113 million more than the company initially filed for a month earlier, and makes it the second largest IPO in the CAR T space; Juno Therapeutics has retained the number-one spot with its $265 million IPO last December.

CAR T-cell therapies are a hot field, with dozens of organizations, including a handful of big pharma companies, working to develop T cells armed with receptors that bind particular cancer-associated antigens. In the last couple of years, hundreds of millions of dollars’ worth of deals have been struck, and dozens of clinical trials initiated. (Read more about the field in this month’s biobusiness article, “The CAR T-Cell Race.”)

Cellectis’s focus is on allogeneic T cells, or those taken from donated samples, in hopes of making an off-the-shelf therapy that can be more widely used than autologous cells. The company got a boost last year when it struck a deal with Pfizer for $80 million up front, plus up to $185 million per product and royalties. In its new IPO, Cellectis priced 5.5 million American shares at $41.50 each, with another 825,000 shares set away for the company’s underwriters. The money will go toward advancing four CAR-T candidates through Phase 1 trials, manufacturing the therapies, and work outside of oncology.

(Hat tip: Fierce Biotech)

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.